Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS
Advice on the use of Danis stent for acute oesophageal variceal bleeds to aid local decision making
Advice on the use of HemaClear for bloodless surgical field during limb surgery to aid local decision making
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Advice on the use of PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection to aid local decision making
Advice on the use of eXroid, using direct current electrotherapy to blood vessels of internal haemorrhoid to shrink haemorrhoids, to aid local decision making
Advice on the use of the OPTIMIZER smart system for managing heart failure to aid local decision making
Advice on the use of superDimension Navigation System to help diagnostic sampling of peripheral lung lesions to aid local decision making
Advice on the use of MR-proADM test for use with clinical deterioration scores in cases of suspected infection to aid local decision making
Advice on the use of Endo-SPONGE for colorectal anastomotic leakage to aid local decision making
Advice on the use of AmnioSense (non-invasive diagnostic pad/liner) for unexplained vaginal wetness in pregnancy to aid local decision making
KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are
KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance
KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE
KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with
KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points
KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:
KTT7 Antipsychotics in people living with dementia Key points The risks and limited
KTT14 Wound care products Key points A large number of wound dressings are available
KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points
KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)
KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can
KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points
KTT20 Safer insulin prescribing Key points Several new insulin products have been launched
KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation
Advice on the use of Optowire (sterile, fibreoptic-based, disposable guide wire) for measuring fractional flow reserve (FFR) to aid local decision making
Advice on the use of Leukomed Sorbact for preventing surgical site infection (SSI) to aid local decision making
Advice on the use of UroShield for preventing catheter-associated urinary tract infections (CAUTI) to aid local decision making
Advice on the use of SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea to aid local decision making
Advice on the use of Alpha-Stim AID for anxiety to aid local decision making
Advice on the use of InterDry for intertrigo (inflammatory skin rash) to aid local decision making
KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points
KTT23 Shared decision making Key points In the context of medicines optimisation, shared
Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making
This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
This guideline covers the assessment and early management of head injury in children, young people and adults. It promotes effective clinical assessment so that people receive the right care for the severity of their head injury, including referral directly to specialist care if needed.
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for adults with multiple sclerosis by promoting symptom management, comprehensive reviews and effective relapse treatment.
This guideline covers diagnosing and managing community- and hospital-acquired pneumonia in adults. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.